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ABSTRACT 
Objective: The current research objective is systematic development and characterization of binary and ternary inclusion complexes of cefuroxime 
axetil with β-cyclodextrin to improve its pharmaceutical characteristics by using the kneading method. 
Methods: Phase solubility study was carried out using Higuchi and Connors method. Based on its result, binary complexes of cefuroxime axetil with 
different ratio of β-cyclodextrin were developed and characterized using differential scanning calorimeter (DSC), fourier transform infrared 
spectroscopy (FT-IR) and X-ray powder diffractometry (XRD). Then, binary complexes were analyzed for in vitro dissolution testing. The ternary 
complexes were developed using different ratio of PVP K-30 as a ternary component and evaluated for in vitro dissolution testing and in vitro taste 
masking. 
Results: Binary complex of cefuroxime axetil with β-cyclodextrin (1:1) showed better drug release than pure drug. During the development of the 
ternary complex, β-cyclodextrin (1:1) and 1% w/v PVP K-30 as a ternary agent resulted in an optimized ternary complex. The DSC, FT-IR and XRD 
studies clearly revealed the formation of binary and ternary complexes. The ternary complex showed better drug release of>85% within 30 min. in 
comparison to binary complex. The in vitro taste-masking study revealed the taste masking efficiency of the ternary complex of cefuroxime with β-
cyclodextrin. 
Conclusion: The developed binary and ternary complex of cefuroxime axetil based on β-cyclodextrin with PVP K-30 showed improved in vitro 
dissolution rate and taste masking in comparison to pure drug. The drug release was better in ternary complexes. The present research work 
successfully shows the utility of binary and ternary complexes for improving pharmaceutical characteristics of cefuroxime axetil. 
Keywords: Cefuroxime axetil, Inclusion complex, Binary complex, Ternary complex, Cyclodextrin, Kneading method, Bioavailability, Beta-
cyclodextrin 
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INTRODUCTION  
The main goal of oral drug delivery systems is to modulate the 
solubility of active pharmaceutical ingredients (APIs) that improve 
the absorption of the drug and its bioavailability also. About 40% of 
the new chemical entity (NCEs) in the pipeline and 60% of newly 
developed APIs are associated with low solubility that results less 
assimilation and bioavailability. The problem of low solubility is 
mainly related to the BCS (Biopharmaceutical Classification System) 
class-II and IV drugs. These drugs show low absorption that leads to 
inconsistent in vitro-in vivo correlation and poor bioavailability. The 
dissolution step is the rate-limiting factor for the assimilation of BCS 
class II drugs, whereas dissolution and permeability both are rate-
limiting factors for BCS class IV drugs. Pharmaceutical researchers 
are constantly working on various approaches for improving the 
drug solubility and dissolution rate of BCS class II drugs, which 
improve the therapeutic responses and overcome the toxic effects 
owing to high dose [1-4]. The currently applied approaches for 
improving the dissolution rate of poorly soluble drugs are 
micronization, nanoformulations, salt formation, prodrug and drug 
derivatization, co solvency, use of surfactants, cyclodextrin 
complexes, change in crystal habit or co-crystals, self-emulsifying 
drug delivery systems, solid dispersions etc [5, 6]. Each technique 
has its own merits and demerits regarding solubility enhancement 
and the selection of suitable one mainly depends on the type of drug, 
polymers, therapeutic, and targeted delivery of drugs which to be 
obtained [7, 8].  
Inclusion complexes have emerged as a viable and fruitful 
alternative for solid dispersions and other techniques for the 
development of solid state forms to improve pharmaceutical 
characteristics such as solubility, chemical stability, bioavailability 
and efficiency. Low toxicity and different cavity sizes of 
cyclodextrins (CDs) make it an important tool for enhancement of 
solubility and bioavailability of drugs [9], besides diminishing 
gastric irritation caused by several medicaments and improvement 
of bitter taste [10, 11]. Various methods are reported in the 
literature, such as co-precipitation, neutralisation, ball-milling, spray 
drying, kneading, freeze-drying, sealed-heating and solvent 
evaporation [12]. In the present investigation, the kneading 
technique was employed since it is an efficient technique for 
protecting medicament from chemical decomposition, lessening loss 
of potential because of low processing temperature and decline 
water content level [13].  
These complexes were earlier known by some other names such as 
“occlusion compounds, adducts and clathrates” then Schlenk, a 
scientist, named the complexes as “inclusion compounds”. The size 
of the guest molecule is an important parameter in this technique 
such as the formation of a stable complex with desired 
physicochemical properties, the size of the guest molecule should be 
comparable to the host molecule so that it can easily entrap into the 
cavity of the host molecule [14]. 
Cyclodextrin complexes have attracted the researcher’s focus for the 
development of inclusion complexes due to several advantages 
accompanied by these formulations. Various technologies have been 
used for the synthesis of cyclodextrin complexes formation such as 
kneading, co-precipitation, solvent evaporation, lyophilization, spray 
drying etc [15, 16]. 
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Cefuroxime axetil (CFA) is a β-lactamase-stable 1-acet-oxyethylester that 
is a prodrug of cefuroxime cephalosporin which is used for treatment of 
respiratory tract infection, pharyngitis, tonsillitis, acute bacterialotitis, 
urinary tract infections and simple skin infection. It consists of 1-
acetoxymethyl ester that helps it in intestinal assimilation [17, 18]. It has 
less aqueous solubility with the bioavailability of 30%-60%. It belongs to 
BCS II class drug with of oral bioavailability of 37% on an empty 
stomach, upto 52% if taken after food with half-life of 1.2-1.6 h [19].  
CDs are macrocyclic oligosaccharides capable for improving the 
solubility and bioavailability for poorly soluble molecules by 
encapsulating guest molecule in its inside void that is lipophilic in 
nature [20-23]. 
For BCS II, the rate-limiting step is medicament discharge from the 
dosage form and its solubility in the GI fluid and not the assimilation; 
thus by improving solubility, bioavailability also improves. Thus, the 
primary objective of the present research is to develop binary and 
ternary inclusion complexes of cefuroxime axetil with β-CD and PVP 
K-30 for improving its pharmaceutical characterization. 
This investigation mainly focused on analysis of physicochemical 
features of the inclusion complexes of CFA with β-CD in the presence 
of PVP K-30 as a ternary component. The complexes were developed 
by kneading technique and characterized by differential scanning 
calorimetry (DSC), FT-IR and X-ray powder diffractometry (XRD).  
MATERIALS AND METHODS 
Materials 
Cefuroxime axetil was obtained as a gift from Sun Pharmaceutical 
laboratories, Gurugram, India. β-CD was purchased from Central 
drug house Ltd, Delhi, India and PVP K-30 from Loba Chemie Pvt. 
Ltd. Mumbai, India. All chemicals and reagents of analytical grades 
were utilized. 
Methods 
Phase solubility studies  
It is mostly employed technique for the investigation of inclusion 
complexation. Its profiles do not authenticate the development of 
inclusion complexes but only depict how the increment in CDs 
concentration influences the solubility of medicament. It also helps in the 
determination of the stoichiometry ratio for drug and cyclodextrin [24].  
According to Higuchi and Connors method, the excess quantity of 
CFA was incorporated to 20 ml of aqueous solutions containing 
various concentrations of β-CD (2-10 mmol. L-1) without the 
addition of PVP K-30. Whatman filter paper was used for the 
filtration of samples which were obtained after shaking of 
suspension on a rotary shaker for 48h at 125 rpm until equilibrium 
is attained. Then, filtered solutions were appropriately diluted and 
investigated under spectrophotometrically (UV–vis 
spectrophotometer) at 281 nm [25-27].  
Equation (1) and (2) are used for the determination of association 
constant (Ks) of complex and CE of β-CD, respectively.  
 …… (1) 
S ° is the solubility of CFA in absence of β-CD.  
“S ° is the intercept and slope is obtained from the phase solubility 
diagram constructed by plotting concentration of drug on y-axis and 
concentration of β-CD on the x-axis.”  
It provides information regarding the stoichiometry for the 
formation of complex.  
 …. (2) 
The primary purpose behind the phase solubility study was to 
determine the stability constants and complexation efficiency, to 
find out which complex is stable among different ratio of CDs in the 
binary complex [28, 29].  
Formulation of binary inclusion complexes  
A fixed amount of the drug and β-CD were weighed as shown in 
table 1. First, β-CD was incorporated to the mortar; a minute 
amount of methanol was also incorporated during trituration to 
obtain slurry-like consistency. Cefuroxime axetil (drug) was 
incorporated slowly into the slurry and triturated for a half-
hour. The obtained paste was dried in a hot air oven for 24 h at 
40 °C, stored in desiccators over fused calcium chloride and 
then, the dried paste was passed through sieve no. 60 and 
packed in the container. Similarly, the preparation of the binary 
complex of molar ratio 1:3 and 1:5 was prepared and packed in 
the container for further analysis [30]. 
 
Table 1: Formulation of binary and ternary complexes 
S. No. Inclusion complexes CFA (mg) β-CD (mg) PVP K-30 (%w/v) 
1.  Binary complex (1:1) 1.021 2.270 - 
2.  Binary complex (1:3) 1.021 6.810 - 
3.  Binary complex (1:5) 1.021 11.350 - 
4.  Ternary complex (0.25%w/v) 1.021 2.270 0.25% 
5.  Ternary complex (0.50% w/v) 1.021 2.270 0.5% 
6.  Ternary complex (1.0 %w/v) 1.021 2.270 1.0% 
 
Characterization 
FT-IR analysis  
FT-IR study of drug, excipients and complexes were carried out with 
(FT-IR Alpha Bruker 1206 0280, Germany) by KBr disc method to 
identify the functional groups present in them. The spectra were 
recorded over the 4000-400 cm-1 range and analyzed [31, 32]. 
DSC study of binary complexes 
DSC measurements were carried out on DSC Q10 V9.9 Build 303 to 
investigate the thermal behavior of samples. This technique is used 
to study the thermal transition of a polymer. For example, the 
melting point of a crystalline polymer, glass transition and 
crystallization temperature. The samples (2 mg) of individual 
substances i.e. CFA, β-CD and complexes, were weighed and 
thematically sealed in flat bottomed aluminum pan with crimped on 
the lid. The pan was placed on the sample holder and an empty pan 
was placed on the reference pan holder of DSC apparatus. The 
samples were heated in an atmosphere of nitrogen gas bypassing it 
at 60 ml/min flow rate over a temperature range from 40-300 °C 
[33, 34].  
XRD analysis of binary complexes 
This study was performed at PW1710 X-ray diffractometer with Cu as 
anode material and graphite monochromator, operated at a voltage of 
35kV, current 40 mA in the 2θ angle range of 10-70 °C with scan time 
of 0.5s. The X-ray diffractogram showed narrow and broad peaks 
reflecting the nature of drugs, excipients and complexes [35].  
Dissolution studies  
This study was conducted in the dissolution test apparatus-II paddle 
(Disso2000 Tablet dissolution test apparatus, Lab India, Mumbai, 
India). 1025 mg of pure CFA/complexes were incorporated into a 
vessel that contained 900 ml of 0.1N HCl, maintained at 37±0.5 °C at 
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50rpm. 5 ml of aliquots were collected at predetermined time 
intervals and filtered through Whatman filter paper, suitably diluted 
and investigated spectrophotometrically (Shimadzu UV–vis 
spectrophotometer 1800, Japan) at 281 nm [36, 37]. 
Preparation and characterization of ternary inclusion 
complexes  
Binary complex of molar ratio 1:1 showed 85.53% release, which 
was more significant than rest two complexes. The formation of 
ternary inclusion complexes of the drug and β-CD in the molar ratio 
of 1:1 was selected for the formulation of a ternary complex with 
PVP-K30. The formulations of ternary complexes is shown in table 2 
and characterized for phase solubility, FT-IR, DSC, PXRD and % CDR 
as performed for binary complexes [38-42]. 
In vitro taste evaluation study 
The objective of taste masking is the reduction/inhibition of the 
interaction between the drug and the taste buds. Dissolution testing 
should be conducted for confirmation of the slow discharge of drug 
in the oral cavity, which is crucial for taste masking of the drug. 
Molecules with high bitter levels have a lower acceptable range of 
drug discharge and vice-versa, thus there is no range for acceptable 
drug release. Slow discharge of the drug results into taste-masking 
due to drug is present in minimal and below the bitterness threshold 
in the oral cavity. In this analysis, the drug is analyzed from the 
dissolution media of phosphate buffer (pH 6.8) at concentrations 
below its bitterness threshold [43-47]. Threshold bitterness 
concentration is the lowest concentration that had a bitter taste. In 
the present study, the bitterness threshold concentration was taken 
from reported literature on cefuroxime axetil [48].  
A quantity of optimized inclusion complex equivalent to 100 mg of 
cefuroxime axetil was incorporated to a volumetric flask containing 
10 ml of phosphate buffer. The mixture was vortexed for 30s, 
filtered and analyzed for cefuroxime axetil concentration at 281 nm 
by UV-Visible spectrophotometer and that was compared with the 
threshold value. For acceptable taste masking, the quantity of 
solubilized medicament within 30s should not be greater than the 
threshold bitterness concentration of the medicament [49]. 
RESULTS 
Phase solubility studies  
The phase solubility diagrams of CFA in aqueous β-CD solution in 
the presence or absence of PVP K-30 demonstrated AL type of 
solubility curve with linear increment in CFA solubility upon 
increment in concentration of β-CD as shown in table 2 and fig. 1. 
  
Table 2: Solubility of cefuroxime axetil with increasing concentration of β-CD 
S. No. β-CD(mmol. L-1) CFA/β-CD(mmol. L-1) CFA/β-CD/PVP K-30 (mmol. L-1) 
1 2 0.78±0.05 0.94±0.06 
2 4 1.03±0.03 1.38±0.03 
3 6 1.49±0.07 1.79±0.06 
4 8 1.72±0.08 2.2±0.12 
5 10 1.93±0.10 2.61±0.04 
(n=3) with mean±SD. 
 
 
Fig. 1: Phase solubility study of binary and ternary complex, (n=3) with mean±SD value 
 
Its slopes were found to be less than 1 which indicates that 1:1 
stoichiometry developed water-soluble complexes [13, 25]. The values 
of S0, slopes, Ks, and CE of complex enhanced with the addition of PVP-
K30 to the complexation media, demonstrating better efficacy of ternary 
over the binary complex. This may be due to electrostatic/hydrogen 
bonding interaction and salt formation of PVP K-30 with β-CD and CFA. 
Apart from this, molecular interactions such as hydrophobic bonding, 
van der waals dispersion forces, which are based on solubilization of the 
medicament that promote the release of high-energy water molecules 
exist in the cavity, might also have responded to valuable effects of PVP-
K30 as a ternary component. This data showed that the system released 
energy upon complexation and the presence of PVP-K30 makes it more 
favorable, signifying its importance as a ternary component for the 
development of ternary complexes. Jagtap et al., also obtained similar 
results in their research [50]. 
FT-IR analysis 
FT-IR analysis of model drug CFA revealed various characteristics peaks 
such as peaks at 1798.40 cm-1 corresponding to amide cefum ring, 
673.96 cm-1 corresponding to–C-S stretching, 1156.82 cm-1 
corresponding to–C-N stretching, 1332.76 cm-1 corresponding to–C=O 
stretching, 3476.72 cm-1 corresponding to–N-H stretching (primary 
amide) and 1601.1 cm-1 for carboxylic C=O stretching for carboxylic 
bond. While β-CD showed its characteristics peaks at 3420.02 cm-
1corresponding to-O-H stretching, 2956.08 cm-1 corresponding to 
aliphatic-C-H stretching, 1077.10 cm-1 corresponding to–C-O stretching. 
PVP K-30 revealed its characteristic peaks at 3278.25 cm-1 
corresponding to stretching vibration of–O-H, 2924.59 cm-1 
corresponding to–CH stretching, 1643.28 cm-1 corresponding to–C=O 
stretching, 1252.18 cm-1 corresponding to-C-N stretching. FT-IR 
spectrum is demonstrated in fig. 2. 
After the formation of complexes, the peaks describing functional 
groups of the drug disappeared or shifted left or right, evidencing 
the entrapment of drug into the cavity of β-CD.  
In FT-IR spectra of binary complexes, alterations in shift, shape and 
extinction of peaks were found that showed the development of 
satisfactory inclusion complex as shown in fig. 2. Among observed 
shifts, it is feasible to list for guest: loss of the peaks at 3420 cm-1 
(OH stretch), 2924 cm-1 and 2834 cm-1 (CH sp3), which authenticate 
the presence of inclusion in host cavity. Moreover, these outcomes 
recommend that a molecule enters in the host by means of the 
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condensed rings A and C, portions with the lowest polarity. The 
intense shift and enhanced intensity of band in 3320 cm-1 also 
confirmed localization of guest in host cavity. In addition, existence 
of 1021 cm-1 peak demonstrates that no chemical interaction 
occurred on the external host face. Similar results were obtained by 
Sapte et al., in their study [51]. 
DSC analysis  
This technique helps in investigating the interaction between a guest 
and host molecules during the formation of the binary complexes. 
Alteration in melting points occurs due to the embedment of guest 
molecules in the cavity of β-CDs. The thermogram of CFA, β-CD and 
binary complexes are demonstrated in fig. 3. The DSC curve of CFA 
exhibited glass transition temperature (Tg) at 81.90 °C that 
indicated its amorphous nature. The presence of a wide endothermic 
peak at 137.52 °C in curve of β-CD was recognized due to losing 
water from β-CD cavity. In DSC of the physical mixture, the band has 
been shifted toward right but showing two endothermic peaks 
evident of no complex formation. The binary complexes had wide 
peaks at 147.18 °C and assignable to loss of water content and loss 
of Tg of CFA confirmed entrapment of CFA inside β-CD cavity with 
water molecules as a substitution. These results justify the presence 
of strong physical interaction between CFA and β-CD and the 
fabrication of stable binary inclusion complexes in solid-state [52]. 
The results obtained are in agreement with the similar study by Ding 
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Fig. 3: DSC spectrum of a) CFA, b) β-CD, c) Physical mixture, d) Binary complex 1:1, e) Binary complex 1:3 and f) Binary complex 1:5 
 
XRD analysis 
The physical state of pure drug and its binary complexes could be 
evaluated by investigating their XRD spectrum, as depicted in fig. 4. The 
diffractogram of CFA showed diffused peaks that confirmed its 
amorphous nature. The diffractogram of β-CD showing peaks at 2θ value 
of 11.94, 12.57, 15.29, 17.07, 19.05, 20.74 and 22.56. The diffractogram 
of the complexes showed no diffused maxima, such as the formation of 
sharp, narrow peaks indicating the crystalline nature of complexes due 
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Fig. 4: XRD spectrum of a) CFA, b) β-CD, c) Binary complex 1:1, d) Binary complex 1:3 and e) Binary complex 1:5 
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Evaluation of ternary inclusion complexes 
FT-IR analysis of ternary complexes 
In inclusion complex formation, no covalent bond is formed as 
demonstrated in fig. 6. Only dipole-dipole interaction, van der waal 
forces and hydrogen bonding are formed. In the complexes, some 
peaks of functional groups of cefuroxime axetil were absent and 
some were shifted from the original range indicating entrapment of 
cefuroxime inside the cavity of beta-cyclodextrin [51].  
DSC study of ternary complexes  
The complexes showed the shifting of the endothermic peak in all 
the thermogram, confirming the development of inclusion 
complexes. The sharp endotherm got converted to broad endotherm 
and shifted to its right as shown in fig. 7 [51].  
XRD analysis 
In ternary complexes, overlapping of β-CD and PVP K-30 
crystalline peaks was observed as shown in fig. 8. However, 
peaks of PVP K-30 were dimmed to a certain extent because of 
solid-state interaction during the development of ternary 
complexes [50]. 
In vitro % cumulative drug release studies of ternary complexes 
This study was conducted in 0.1N HCl using the USP-II apparatus at 
37±2 °C and at 50 rpm for ternary complexes. Results of in vitro % 
cumulative drug release of ternary complexes with different 
concentrations of PVP K-30 are shown in fig. 9. 
In vitro % cumulative drug release studies of ternary complexes 
showed the best dissolution in complex having 1% w/v PVP K-30. 
The release is much higher because of the hydrophilic nature of 
polyvinylpyrrolidone. As the concentration of PVP K-30 increases, 
the dissolution of complexes also gets increased. But, there was no 
role of PVP K-30 to mask the bitterness of cefuroxime axetil. 
Prabhakaran et al., also found similar results that authenticate the 
accuracy of the results [51]. 
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Fig. 8: XRD spectrum of a) Ternary complex with 0.25% PVP, b) Ternary complex with 0.5% PVP and c) Ternary complex with 1% PVP 
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In vitro taste evaluation study  
The reported bitterness threshold value of CFA is 40μg/ml [49]. A 
quantity of prepared ternary inclusion complex equivalent to 100 mg 
of CFA was incorporated to a volumetric flask consisting of 100 ml of 
6.8 phosphate buffer. The mixture was vortexed for 30s, filtered and 
analyzed. The amount of CFA dissolved in the phosphate buffer was 
detected to be 37.23μg/ml, which is below the threshold value at the 
end of 30s, indicating the masking of the bitter taste of the drug [54]. 
CONCLUSION  
In this study, the binary and ternary complexes of cefuroxime axetil 
were prepared by the kneading method. It was concluded that PVP 
K-30 can act as a ternary component for improving the 
pharmaceutical characteristics of CFA with β-CD. Ternary complexes 
resulted in a better dissolution profile than binary complexes 
with>85% drug release within 30 min owing to the positive effect of 
incorporation of basic PVP K-30, which drastically improved phase 
solubility parameters like Ks and CE, interacting simultaneously 
both with β-CD (via H-bonding) and CFA (via electrostatic 
interactions and salt formation). The in vitro taste-masking study 
also revealed that the ternary complex was able to mask the bitter 
taste of the drug. Thus, it can be concluded that ternary systems of 
CFA with β-CD and PVP K-30 is a viable method for improving the 
pharmaceutical characteristics of cefuroxime axetil. 
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